Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings (MEDP) is a leading global clinical research organization accelerating drug development through full-service trial management. This page provides investors and industry professionals with timely updates on MEDP's clinical trial milestones, regulatory developments, and strategic partnerships.
Access official press releases and curated analysis covering key operational areas including therapeutic research advancements, bioanalytical innovations, and global trial management. Our repository ensures transparent tracking of MEDP's progress in oncology, cardiology, and rare disease research sectors.
Discover updates across critical categories: quarterly financial results, FDA submission announcements, international trial initiations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of MEDP's role in advancing clinical research. For real-time updates, consider enabling notifications or subscribing to our institutional research alerts.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported robust financial results for Q1 2023, with revenue of $434.1 million, up 31.2% year-over-year. The company achieved a net book-to-bill ratio of 1.28x, with net new business awards of $555.8 million, a 31.4% increase. GAAP net income rose to $72.9 million or $2.27 per diluted share, compared to $61.3 million or $1.69 per diluted share last year. EBITDA increased 31.9% to $92.8 million, yielding an EBITDA margin of 21.4%. The company projects 2023 revenue between $1.745 billion and $1.805 billion, reflecting growth of 19.5% to 23.6%.
Cash flow from operations reached $80.1 million, with a remaining $332.7 million for share repurchase. Medpace will host a conference call on April 25, 2023, to further discuss these results.
Medpace Holdings (Nasdaq: MEDP) will report its Q1 2023 financial results on April 24, 2023, after market close. A conference call is scheduled for April 25, 2023, at 9:00 a.m. ET to discuss these results. Interested participants can register in advance through a provided link and are encouraged to join 10 minutes early. The call will also be accessible via webcast on Medpace's investor relations website, where a replay will be available afterwards. Additionally, a supplemental slide presentation will be posted on the site prior to the call.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 27.7% increase in fourth-quarter 2022 revenue, reaching $394.1 million, compared to $308.6 million in Q4 2021. The net income for Q4 2022 rose to $68.7 million or $2.12 per diluted share, up from $50.0 million or $1.32 per diluted share the previous year. Full-year 2022 revenue was $1,460.0 million, a 27.8% increase. The company forecasts 2023 revenue between $1.690 billion and $1.750 billion, implying growth of 15.8% to 19.9%.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.
Medpace Holdings, Inc. (NASDAQ: MEDP) reported third-quarter 2022 revenue of $383.7 million, up 29.8% year-over-year. Net new business awards reached $470.9 million, yielding a net book-to-bill ratio of 1.23x. GAAP net income was $66.0 million or $2.05 per diluted share, compared to $48.6 million or $1.29 in Q3 2021, with a net income margin of 17.2%. EBITDA increased 48.5% to $89.3 million. The outlook for 2022 anticipates revenue of $1.440 billion to $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its third quarter 2022 financial results after market close on October 24, 2022. A conference call will follow on October 25, 2022, at 9:00 a.m. ET to discuss these results. Interested parties can register here. A supplemental slide presentation will be available in the 'Investors' section of their website.
Medpace Holdings, Inc. (MEDP) reported a revenue of $351.2 million for Q2 2022, a 26.2% increase from $278.3 million a year earlier. Net new business awards rose by 16.3% to $450.6 million, achieving a net book-to-bill ratio of 1.28x. The company posted a GAAP net income of $49.4 million, or $1.46 per diluted share, marking a significant increase from the $39.9 million in Q2 2021. EBITDA climbed 42.0% to $68.1 million, equating to a margin of 19.4%. Medpace forecasts 2022 revenue between $1.405 billion and $1.435 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its Q2 2022 financial results on July 25, 2022, after market close. A conference call is scheduled for July 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can register via a provided link or join through the investors section of the Medpace website. A supplemental slide presentation will also be made available ahead of the call. Medpace is a full-service clinical contract research organization focusing on biotechnology, pharmaceuticals, and medical devices.
Medpace Holdings reported a 27.3% increase in revenue for Q1 2022, reaching $330.9 million, up from $260.0 million in Q1 2021. The company achieved net new business awards of $423.0 million, resulting in a net book-to-bill ratio of 1.28x. GAAP net income rose to $61.3 million ($1.69 per diluted share), compared to $43.3 million ($1.14 per diluted share) last year. EBITDA increased by 31.3% to $70.4 million, with a margin of 21.3%. The firm forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace (MEDP), a clinical research organization, has partnered with Matthew 25: Ministries to support humanitarian efforts in Ukraine. The organization donated over
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
